• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

20.88 +2.34 (+12.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
August 27, 2025
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
What Does the Market Think About Beam Therapeutics?
August 25, 2025
 
Via Benzinga
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
August 25, 2025
From Beam Therapeutics
Via GlobeNewswire
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
August 15, 2025
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
August 14, 2025
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
August 05, 2025
From Beam Therapeutics
Via GlobeNewswire
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
June 28, 2025
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies
June 27, 2025
Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox. 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
June 13, 2025
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
June 11, 2025
 
Via Benzinga
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
June 03, 2025
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 29, 2025
From Beam Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
May 23, 2025
Via Investor Brand Network
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
May 14, 2025
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 12, 2025
From Beam Therapeutics
Via GlobeNewswire
10 Analysts Assess Beam Therapeutics: What You Need To Know
May 07, 2025
 
Via Benzinga
Why Beam Therapeutics Stock Tanked on Tuesday
May 06, 2025
Via The Motley Fool
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 06, 2025
From Beam Therapeutics
Via GlobeNewswire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
April 21, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
April 21, 2025
 
Via Benzinga
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
April 07, 2025
Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND 
Via Benzinga
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
April 05, 2025
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
April 04, 2025
 
Via Benzinga
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'
April 04, 2025
 
Via Benzinga
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
March 28, 2025
 
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
March 28, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap